Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 11/20 | 0.64 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.61 |
| ▸ | CASP2 | P42575 | 1/20 | 0.57 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.56 |
| ▸ | NAAA | Q02083 | 2/20 | 0.53 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.53 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10916993 | 1.00 | EPHX1 (0.64) | EPHX1PLA2G2ACASP2PLA2G4ANAAA | |
| SCHEMBL8293274 | 1.00 | EPHX1 (0.64) | EPHX1PLA2G2ACASP2PLA2G4ANAAA | |
| SCHEMBL8293276 | 1.00 | EPHX1 (0.64) | EPHX1PLA2G2ACASP2PLA2G4ANAAA | |
| SCHEMBL10488375 | 1.00 | EPHX1 (0.64) | EPHX1PLA2G2ACASP2PLA2G4ANAAA | |
| SCHEMBL12266952 | 1.00 | EPHX1 (0.64) | EPHX1PLA2G2ACASP2PLA2G4ANAAA | |
| SCHEMBL10920434 | 1.00 | EPHX1 (0.64) | EPHX1PLA2G2ACASP2PLA2G4ANAAA | |
| SCHEMBL12266953 | 1.00 | EPHX1 (0.64) | EPHX1PLA2G2ACASP2PLA2G4ANAAA | |
| SCHEMBL11419656 | 1.00 | EPHX1 (0.64) | EPHX1PLA2G2ACASP2PLA2G4ANAAA | |
| SCHEMBL7876750 | 0.98 | EPHX1 (0.60) | EPHX1PLA2G2ACASP2PLA2G4ANAAA | |
| Hydrochloric Acid SCHEMBL27164090 | 0.95 | EPHX1 (0.58) | EPHX1PLA2G2ACASP2PLA2G4ANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2932981-B1 | Albumin-binding derivatives of GLP-1 | NOVO NORDISK AS (DK) | 2021-06-16 | — | — | EP | disclosed |
| US-20190000923-A1 | METHODS OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-01-03 | — | — | US | disclosed |
| WO-2017109706-A1 | METHODS OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) | NOVARTIS AG (CH) | 2017-06-29 | — | — | WO | disclosed |
| US-20160108102-A1 | Novel GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2016-04-21 | — | — | US | disclosed |
| US-20160108102-A1 | Novel GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2016-04-21 | — | — | US | disclosed |
| EP-2932981-A2 | Albumin-binding derivatives of GLP-1 | NOVO NORDISK A/S (DK) | 2015-10-21 | — | — | EP | disclosed |
| US-20130244931-A1 | Novel GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2013-09-19 | — | — | US | disclosed |
| US-20130244931-A1 | Novel GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2013-09-19 | — | — | US | disclosed |
| US-20130053315-A1 | NOVEL GLP-1 DERIVATIVES | NOVO NORDISK A/S | 2013-02-28 | — | — | US | disclosed |
| US-20130053315-A1 | NOVEL GLP-1 DERIVATIVES | NOVO NORDISK A/S | 2013-02-28 | — | — | US | disclosed |
| US-20130040884-A1 | ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG | NOVO NORDISK A/S | 2013-02-14 | — | — | US | disclosed |
| US-20130040884-A1 | ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG | NOVO NORDISK A/S | 2013-02-14 | — | — | US | disclosed |
| US-20100305032-A1 | Novel GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2010-12-02 | — | — | US | disclosed |
| US-20100305032-A1 | Novel GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2010-12-02 | — | — | US | disclosed |
| US-20070203058-A1 | Novel Glp-1 Derivatives | NOVO NORDISK A/S (DK) | 2007-08-30 | — | — | US | disclosed |
| US-20070203058-A1 | Novel Glp-1 Derivatives | NOVO NORDISK A/S (DK) | 2007-08-30 | — | — | US | disclosed |
| WO-2005027978-A2 | ALBUMIN-BINDING DERIVATIVES OF THERAPEUTIC PEPTIDES | NOVO NORDISK A/S (DK) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040884-A1 | ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG | FABP1, FABP2, FABP4 | EPHX1 2765/4885PLA2G2A 625/4885CASP2 3112/4885 |
| US-20130053315-A1 | NOVEL GLP-1 DERIVATIVES | GLP1R, GIPR, IAPP | EPHX1 4295/4885PLA2G2A 1316/4885CASP2 615/4885 |
| US-20190000923-A1 | METHODS OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) | HDGF, FABP1, GLS2 | EPHX1 4381/4885PLA2G2A 2642/4885CASP2 3015/4885 |
| US-20160108102-A1 | Novel GLP-1 Derivatives | GLP1R, GIPR, IAPP | EPHX1 4295/4885PLA2G2A 1316/4885CASP2 615/4885 |
| US-20100305032-A1 | Novel GLP-1 Derivatives | GLP1R, GIPR, IAPP | EPHX1 4295/4885PLA2G2A 1316/4885CASP2 615/4885 |
| US-20070203058-A1 | Novel Glp-1 Derivatives | GLP1R, GIPR, NPY4R | EPHX1 2354/4885PLA2G2A 3975/4885CASP2 3627/4885 |
| US-20130244931-A1 | Novel GLP-1 Derivatives | GLP1R, GIPR, IAPP | EPHX1 4295/4885PLA2G2A 1316/4885CASP2 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.